Start Date: 18/08/2015
End Date: 18/08/2015
Venue: Saïd Business School, Oxford, OX1 1HP
Since the discovery that our genes hold the keys to our health, the race has been on to find a precise method to edit our genomes. CRISPR provides the tools to precisely edit genomes with unparalleled simplicity and flexibility, resulting in the potential for a revolutionary step towards curing hereditary disorders and correcting mutations that cause cancer. This breakthrough gene editing technology is barely 3 years old, however it has already attracted tens of millions of dollars from investors, inspiring a multitude of exciting biotech start-ups.
Join us for what is certain to be an informative and inspiring discussion about how entrepreneurs, academics and industry professionals can join in with the battle to exploit the biggest biotech discovery of the decade.
Attendance is FREE to all OB Members, and tickets are guaranteed to sell out once they are released!
Dr Lorenz Mayr, Vice President, Global Head, Biological Reagents & Assay Development, AstraZeneca
Eric Rhodes, Senior Vice President, Chief Technology Officer, Horizon Discovery
Prof Tudor Fulga, Associate Professor of Genome Biology, University of Oxford
Dr Philip Webber, Partner, Dehns (Patent and Trademark Attorney)
Edward Perello, Co-Founder, Chief Business Officer, Desktop Genetics